{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:53:04Z","timestamp":1785214384540,"version":"3.55.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"HHS | National Institutes of Health","award":["S10OD030245,P30 CA010815"],"award-info":[{"award-number":["S10OD030245,P30 CA010815"]}]},{"name":"Canadian Government | Canadian Institutes of Health Research","award":["CIHR PJT-153057"],"award-info":[{"award-number":["CIHR PJT-153057"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              We have synthesized a novel and highly selective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease peptide mimetic inhibitor mimicking the replicase 1ab recognition sequence -Val-Leu-Gln- and utilizing a cysteine selective acyloxymethyl ketone as the electrophilic warhead to target the active site Cys145. Utilizing a constrained cyclic peptide that locks the conformation between the P3 (Val) and P2 (Leu) residues, we identified a highly selective inhibitor that fills the P2 pocket occupied by the leucine residue sidechain of PF-00835231 and the dimethyl-3-azabicyclo-hexane motif in nirmatrelvir (PF-07321332). This strategy resulted in potent and highly selective Mpro inhibitors without inhibiting essential host cathepsin cysteine or serine proteases. The lead prototype compound 1 (MPro IC\n              <jats:sub>50<\/jats:sub>\n              = 230 \u00b1 18 nM) also inhibits the replication of multiple SARS-CoV-2 variants\n              <jats:italic>in vitro<\/jats:italic>\n              , including SARS-CoV-2 variants of concern, and can synergize at lower concentrations with the viral RNA polymerase inhibitor, remdesivir, to inhibit replication. It also reduces SARS-CoV-2 replication in SARS-CoV-2 Omicron-infected Syrian golden hamsters without obvious toxicities, demonstrating\n              <jats:italic>in vivo<\/jats:italic>\n              efficacy. This novel lead structure provides the basis for optimization of improved agents targeting evolving SARS-CoV-2 drug resistance that can selectively act on Mpro versus host proteases and are less likely to have off-target effects due to non-specific targeting. Developing inhibitors against the active site of the main protease (Mpro), which is highly conserved across coronaviruses, is expected to impart a higher genetic barrier to evolving SARS-CoV-2 drug resistance. Drugs that selectively inhibit the viral Mpro are less likely to have off-target effects warranting efforts to improve this therapy.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00562-24","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:00:51Z","timestamp":1725368451000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Design of novel and highly selective SARS-CoV-2 main protease inhibitors"],"prefix":"10.1128","volume":"68","author":[{"given":"Adi N. R.","family":"Poli","sequence":"first","affiliation":[{"name":"Medicinal Chemistry, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-6490","authenticated-orcid":true,"given":"Ian","family":"Tietjen","sequence":"additional","affiliation":[{"name":"HIV-1 Program in the Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh K.","family":"Nandwana","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Cassel","sequence":"additional","affiliation":[{"name":"The Wistar Cancer Center Molecular Screening, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy E.","family":"Messick","sequence":"additional","affiliation":[{"name":"The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emery T.","family":"Register","sequence":"additional","affiliation":[{"name":"HIV-1 Program in the Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Keeney","sequence":"additional","affiliation":[{"name":"HIV-1 Program in the Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rajaiah","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul K.","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabita","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpan","family":"Acharya","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddappa N.","family":"Byrareddy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Montaner","sequence":"additional","affiliation":[{"name":"HIV-1 Program in the Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-5980","authenticated-orcid":true,"given":"Joseph M.","family":"Salvino","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, The Wistar Institute, Philadelphia, Pennsylvania, USA"},{"name":"The Wistar Cancer Center Molecular Screening, The Wistar Institute, Philadelphia, Pennsylvania, USA"},{"name":"Molecular and Cellular Oncogenesis (MCO) Program, The Wistar Institute, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00069-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65365"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.042"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20542-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01348-19"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.671263"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2646"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.19424-0"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310875200"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2011.10.002"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.04.006"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c08060"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9701637"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja101358s"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00049a001"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9601516"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr010182v"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19662-4"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.34.1128"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.34.3747"},{"key":"e_1_3_4_31_2","first-page":"2535","article-title":"Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug","volume":"10","author":"Wang YC","year":"2020","unstructured":"Wang YC, Yang WH, Yang CS, Hou MH, Tsai CL, Chou YZ, Hung MC, Chen Y. 2020. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug. Am J Cancer Res 10:2535\u20132545.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00233a007"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.05.021"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01063"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0356-z"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-21"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087057116671509"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107940"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013031"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00117"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c04626"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01758-8"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6858"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.806"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00562-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00562-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:45:27Z","timestamp":1728402327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00562-24"}},"subtitle":[],"editor":[{"given":"Miguel Angel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,8]]}},"alternative-id":["10.1128\/aac.00562-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00562-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00562-24"}}